| (Values in U.S. Thousands) | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 | Sep, 2015 |
| Sales | -9,999,000 | 4,480 | 1,870 | 6,420 | 2,080 |
| Sales Growth | -223,291.91% | +139.57% | -70.87% | +208.65% | -17.46% |
| Net Income | -9,999,000 | -9,030 | -12,660 | -7,640 | -10,160 |
| Net Income Growth | -110,630.91% | +28.67% | -65.71% | +24.80% | +2.96% |
Bind Therapeutics (BINDQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
DNIB Unwind, Inc. is a therapeutics company. It developed therapeutics for the treatment of cancer primarily in the United States and Russia. DNIB Unwind, Inc., formerly known as BIND Therapeutics Inc., is based in Cambridge, Massachusetts.
Fiscal Year End Date: 12/31